Abstract
Purpose In this study, we analyzed correlations between 28-day mortality and hemodynamic changes, measured using polymyxin B-immobilized fiber column direct hemoperfusion initiation time, in patients with cancer with refractory septic shock.
Materials and methods We retrospectively analyzed 45 patients with cancer who received polymyxin B-immobilized fiber column direct hemoperfusion due to refractory septic shock. Patients were categorized into early (<12 h between refractory septic shock and initiation of polymyxin B-immobilized fiber column direct hemoperfusion) and late (>12 h) initiation groups. Changes in vasoactive inotrope scores, sequential organ failure assessment scores, and PaO2/FiO2 ratios before and 24 h after polymyxin B-immobilized fiber column direct hemoperfusion, were compared.
Results Univariable analysis showed that 28-day mortality risk was associated with diabetes mellitus (odds ratio=3.081; 95% confidence interval =1.290–7.360; p=0.011), lactic acid (odds ratio=1.010; 95% confidence interval =1.005– 1.014; p<0.0001), and sequential organ failure assessment score (odds ratio=1.190; 95% confidence interval =1.044–1.357; p=0.009). Multivariable analysis showed that 28-day mortality risk was associated with diabetes mellitus (odds ratio=2.718; 95% confidence interval =1.013–7.291; p=0.047), early initiation (odds ratio=0.268; 95% confidence interval =0.094–0.765; p=0.014), and lactic acid (odds ratio=1.009; 95% confidence interval =1.004– 1.014; p<0.0001). Overall survival was slightly higher in the early than in the late initiation group (p=0.0515). Comparisons of variables before and 24 h after polymyxin B-immobilized fiber column direct hemoperfusion revealed that vasoactive inotrope scores decreased in both the early and late groups (Δ318 vs. Δ114; p=0.001 and p=0.005, respectively), whereas the PaO2/FiO2 ratio slightly increased (Δ127.5 vs. Δ95.6; p=0.350 and p=0.390, respectively) over time.
Conclusions In patients with cancer with refractory septic shock, early initiation of polymyxin B-immobilized fiber column direct hemoperfusion reduced inotrope-vasopressor requirement and 28-day mortality.
Competing Interest Statement
The authors have declared that no competing interests exist.
Funding Statement
This work was supported by the National Cancer Center, Korea (NCC grant: 2212490-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Reviewer Board of the National Cancer Center(Approval No,: NCC 2023-0170).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data availability
All data generated or analyzed during this study are included in this published article.
